secwatch / observer
8-K filed June 17, 2026, 4:05 PM ET ticker OM CIK 0001484612
other material confidence high sentiment positive materiality 0.70

Outset Medical secures ~$40M HCA commitment for Tablo hemodialysis system refresh through 2028

Outset Medical, Inc.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Outset Medical, Inc. updated its 2026 guidance (reaffirmed).

Period
2026
Guidance
reaffirmed
Result
guidance update
Exact text from the filing
The Company is reiterating previously issued guidance for 2026, and plans to provide additional detail regarding the 2026 financial impact of the Amendment later in the year once it has visibility to the timing and ramp of the implementation.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Outset Medical, Inc. amended Refresh Amendment with HCA Management Services, L.P. valued at approximately $40 million (effective 2026-06-14).

Action
amendment
Agreement
supply
Counterparty
HCA Management Services, L.P.
Value
approximately $40 million
Effective
2026-06-14
Exact text from the filing
On June 14, 2026, Outset Medical, Inc., (the “Company”) entered into the Refresh Amendment (the “Amendment”) to the Purchasing Agreement with HCA Management Services, L.P. (“HCA”), dated May 1, 2020, as amended (collectively, the “Agreement”). Under the terms of the Amendment, the parties have agreed, among other things, for HCA to refresh its existing fleet of Tablo Hemodialysis Systems by purchasing new Tablo Hemodialysis Systems commencing in 2026 through the end of 2028, for an aggregate contract value, net of rebates and allowances, of approximately $40 million.
View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

Outset Medical, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-26-274135
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.